Clinical use of cystine supersaturation measurements

被引:72
作者
Nakagawa, Y [1 ]
Asplin, JR
Goldfarb, DS
Parks, JH
Coe, FL
机构
[1] Univ Chicago, Sch Med, Chicago, IL 60637 USA
[2] New York Dept Vet Affairs Med Ctr, New York, NY USA
关键词
cystine; cystinuria; urine; kidney calculi;
D O I
10.1016/S0022-5347(05)67011-5
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We measured the concentration and solubility of cystine in urine from patients with cystinuria or calcium stones and from normal subjects to determine whether urine cystine supersaturation can be calculated from a standard nomogram of solubility versus pH or needs to be measured directly. We also evaluated whether increasing pH of the 24-hour collection recovered enough crystallized cystine to increase cystine supersaturation. Materials and Methods: Cystine concentration, pH and usual stone risk factors were measured on 50 ml. aliquots of 24-hour collections from 24 patients with cystinuria, 22 calcium stone formers and 15 normal subjects. After 48 hours of incubation with sodium bicarbonate, a second aliquot was taken from the 24-hour collection for cystine concentration. The original urine at its ambient pH was incubated with an excess of cystine crystals for 24, 48, 72 or 96 hours at 37C to determine solubility and kinetics of equilibration. Results: Cystine solubility varied so widely at any pH range that no predictive nomogram could be relied on for calculating supersaturation. Addition of sodium bicarbonate to the 24-hour urine significantly increased cystine concentration. Urine from stone formers had higher cystine solubility than urine from normal subjects. Conclusions: Clinical management of cystinuria can be improved by direct measurement of cystine solubility because it varies widely at any given pH. Increasing 24-hour collection pH with sodium bicarbonate additionally improves accuracy of supersaturation measurement by recovering crystallized cystine.
引用
收藏
页码:1481 / 1485
页数:5
相关论文
共 17 条
[1]  
Bisceglia L, 1997, AM J HUM GENET, V60, P611
[2]  
Coe FL, 1996, KIDNEY STONES MED SU
[3]  
DENT C E, 1955, Br J Urol, V27, P317, DOI 10.1111/j.1464-410X.1955.tb03486.x
[4]   Mutations in the genomic deoxyribonucleic acid for SLC3A1 in patients with cystinuria [J].
Gitomer, WL ;
Reed, BY ;
Ruml, LA ;
Sakhaee, K ;
Pak, CYC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (10) :3688-3694
[5]   Recent advances in the biochemical and molecular biological basis of cystinuria [J].
Gitomer, WL ;
Pak, CYC .
JOURNAL OF UROLOGY, 1996, 156 (06) :1907-1912
[6]  
Gitomer WL, 1998, HUM MUTAT, pS69
[7]  
GLEESON MJ, 1992, DISORDERS BONE MINER, P801
[8]   Cystinuria subtype and the risk of nephrolithiasis [J].
Goodyer, P ;
Saadi, I ;
Ong, P ;
Elkas, G ;
Rozen, R .
KIDNEY INTERNATIONAL, 1998, 54 (01) :56-61
[9]   PROSPECTIVE ANALYSIS AND CLASSIFICATION OF PATIENTS WITH CYSTINURIA IDENTIFIED IN A NEWBORN SCREENING-PROGRAM [J].
GOODYER, PR ;
CLOW, C ;
READE, T ;
GIRARDIN, C .
JOURNAL OF PEDIATRICS, 1993, 122 (04) :568-572
[10]   CLINICAL COURSE AND CYSTINE STONE FORMATION DURING TIOPRONIN TREATMENT [J].
LINDELL, A ;
DENNEBERG, T ;
HELLGREN, E ;
JEPPSSON, JO ;
TISELIUS, HG .
UROLOGICAL RESEARCH, 1995, 23 (02) :111-117